NCT05486481 2025-03-06
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
Phase 1/2 Withdrawn
Clinical Trials
4 trialsNCT03701321 2023-09-26
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05205252 2023-08-15
ARIA
Ipsen
Phase 1/2 Withdrawn
NCT05408026 2023-01-27
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Alliance Foundation Trials, LLC.
Phase 1/2 Withdrawn